Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038048 · ClinicalTrials.gov registry record · NA
30g vs 33g Needle for Intravitreal Injections
A NA study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03038048: Completed NA study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Wills Eye.
NCT03038048 is a NA study of Age-related Macular Degeneration and Diabetic Macular Edema that has completed, run by Wills Eye. The registered enrollment target is 50 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03038048, a NA study of Age-related Macular Degeneration and Diabetic Macular Edema, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina vein occlusions.
Primary Outcome
Intravitreal injection study pain questionnaire to evaluate discomfort associated with intravitreal injections
Conditions Studied
Interventions
- PROCEDURE Varying needle size with intravitreal ranibizumab or aflibercept
Study Locations (1)
Pennsylvania
- Mid Atlantic Retina- Wills Eye Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2017-04-27 |
| Phase | NA |
What the finished NCT03038048 record still lists
NCT03038048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Varying needle size with intravitreal ranibizumab or aflibercept is the first listed.
NCT03038048 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03038048 about?
NCT03038048 is a clinical study titled "30g vs 33g Needle for Intravitreal Injections". We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina vein occlusions.
What is the current status of trial NCT03038048?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2017-01-27. Estimated completion is 2017-04-27.
What conditions does trial NCT03038048 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion.
What interventions are being tested in trial NCT03038048?
The interventions under investigation include: Varying needle size with intravitreal ranibizumab or aflibercept (PROCEDURE).
Who is sponsoring clinical trial NCT03038048?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03038048 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03038048's enrollment target sits among peer trials
50 48th of 74 higher than 25 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI